Abstract: The invention provides a composition (e.g., pharmaceutical composition) comprising a combination of two or more phages, wherein the phages are two or more of: (a) phage D29; (b) phage Adephagia?41?43; (c) phage Fionnbharth?47; (d) phage Fred313cpm-1; and (e) phage MuddyHRMN0052-1; and a pharmaceutically acceptable carrier. The invention provides a method of treating, reducing, or preventing a disease caused by Mycobacterium tuberculosis in a mammal comprising administering a pharmaceutical composition comprising a combination of two or more phages wherein the phages are two or more of: (a) phage D29; (b) phage Adephagia?41?43; (c) phage Fionnbharth?47; (d) phage Fred313cpm-1; and (e) phage MuddyHRMN0052-1; and a pharmaceutically acceptable carrier. The composition can be administered alone or in combination with one or more antibiotics, wherein the length of treatment is reduced as compared to the length of treatment with one or more antibiotics alone.

Abstract: Disclosed are methods and kits for evaluating predicting whether an individual IPF has slowly or rapidly progressive IPF.

Abstract: A method for treating an ocular disorder in a subject comprising administering a therapeutic agent-loaded carrier to an ocular site of the subject in need thereof, wherein the therapeutic agent loaded-carrier provides controlled delivery of the therapeutic agent under conditions suitable for recruiting regulatory T cells to an ocular region of interest or inducing regulatory T cells in an ocular region of interest.

Abstract: A method of managing data during execution of an application for use in a system that includes a host memory, a near memory, and a near device associated with the near memory. The application uses a working set of data that is distributed between the far memory and the near memory. The method includes counting a number of times that the near device accesses a unit of the working set of data from the far memory, determining whether the number of times exceeds a dynamically changing access counter threshold, wherein the dynamically changing access counter threshold is calculated dynamically based on a static threshold that is set for the system, and responsive to determining that the number of times exceeds the dynamically changing access counter threshold, migrating the unit of data from the far memory to the near memory.

Abstract: A method of characterizing cellular phenotypes includes receiving multi-parameter cellular and sub-cellular imaging data for a number of tissue samples from a number of patients or a number of multicellular in vitro models, performing cellular segmentation on the multi-parameter cellular and sub-cellular imaging data to create segmented multi-parameter cellular and sub-cellular imaging data, and performing recursive decomposition on the segmented multi-parameter cellular and subcellular imaging data to identify a plurality of computational phenotypes. The recursive decomposition includes a plurality of levels of decomposition with each level of decomposition including soft/probabilistic clustering and spatial regularization, and each cell in the segmented multi-parameter cellular and subcellular imaging data is probabilistically assigned to one or more of the plurality of computational phenotypes.

Abstract: Disclosed is a method for administering a transgene into a fibroblast in a subject comprising: a) providing a herpes simplex virus (HSV) comprising a recombinant herpes simplex virus genome, wherein said recombinant herpes simplex virus genome comprises one or more transgenes encoding a polypeptide to be expressed in said fibroblast; and b) providing a pharmaceutically acceptable carrier; wherein said HSV has reduced cytotoxicity as compared to a wild-type herpes simplex virus.

Abstract: The present disclosure provides interleukin-36 (IL-36) cytokine (e.g., IL-36?) expressing oncolytic viruses, and compositions comprising thereof. The present disclosure further provides methods of using said oncolytic viruses and compositions for treating cancer, and for improving a subject's responsiveness to an immunomodulatory agent.

Abstract: A method for treating a neurodegenerative disease or an inflammatory disorder in a subject, comprising administering to the subject in need thereof, a compound, or a pharmaceutically acceptable salt thereof, of formula II: wherein each of R3-R7 is independently H, halogen, optionally-substituted alkyl, amino, alkoxy or hydroxy; R8 is an optionally-substituted heterocycloalkyl; and a is 0 to 3.

Abstract: A method for sustained delivery of an agent to an ocular organ in a subject, comprising topically delivering to the ocular surface a liquid thermoresponsive hydrogel comprising agent-loaded polymer microparticles, wherein the agent is an antibody, a fusion protein, a chemokine, an interleukin, a growth factor, albumin, immunoglobulin, an interferon, a peptide, stem cell-conditioned media, plasma or serum.

Abstract: A method of forming a microneedle array can include forming a microneedle array having one or more chemotherapeutic agents. The microneedle array can include a base portion and plurality of microneedles extending from the base portion, and the one or more chemotherapeutic agents can be present in a higher concentration in the plurality of microneedles than in the base portion.

Abstract: An endovascular apparatus can comprise an array of emitters configured to emit light at a predetermined wavelength and an array of sensors configured to detect light emitted by the emitters and reflected off a surface. The device can be configured to be inserted into a stent within a blood vessel of a patient and the device can be configured to detect the location of a branch blood vessel based on the reflected light detected by the array of sensors. Some devices detect light through a stent wall from an emitter positioned in the branch vessel. Some devices include fiber optics or phototransistors for receiving light from the emitter. Some devices include a fenestration former and a guidewire director along with the light receivers all in one endovascular device.

Abstract: A data management method wherein a working set is distributed between near and far memories includes migrating first data from the far to the near memory according to a prefetcher algorithm. The first data (a subset of the working set) is maintained in the near memory in data structures according to predetermined semantics of the prefetcher that dictate that certain of the first data is prefetched when a first function evaluates as true. The method further includes detecting that the near memory has reached capacity, and in response, adaptively migrating a portion of the first data out of the near and into the far memory according to an eviction algorithm that is based on the set of prefetcher semantics such that certain of the portion of the first data is evicted when a second function evaluates as true, wherein the second function equals the inverse of the first function.

Abstract: Compositions that include a globin, such as hemoglobin, in a relaxed state are described. Globin molecules in a relaxed state (R state) have a higher binding affinity for carbon monoxide and oxygen than globin molecules in a tense state (T state). Hemoglobin in a relaxed state can be, for example, hemoglobin that is substantially free of 2,3-diphosphoglycerate or hemoglobin that includes a ?-Cys93 that is covalently modified to inhibit one or both salt bridges between ?-Asp94, ?-His146 and ?-Lys40. Methods for using these compositions, such as for treating carbon monoxide poisoning, and methods for producing these compositions, are also disclosed.

Abstract: The present disclosure describes multivalent antibacterial vaccines for the treatment of bacterial infections, such as Klebsiella, E. coli and E. cloacae, as well as therapy-resistant forms thereof.

Abstract: Hip tethering devices comprise a femoral implant including a housing that anchors the femoral implant to the femur, at least one spring, and a slider, such that the slider can move relative to the housing via compression and expansion of the at least one spring. A tether has a first end that anchors to the acetabulum, the tether passes through the femoral head, and a second end couples to the slider of the femoral implant, such that the tether spans across the patient's hip joint and relative motion between the slider and the housing allows a limited degree of separation of the femoral head from the acetabulum, while the at least one spring applies a variable tension load to the tether that resists separation of the femoral head from the acetabulum.

Abstract: The invention relates to endovascular medical implant devices and materials of composition for forming these devices to provide improved mechanical properties and biodegradability. The devices include a combination or integration of superelastic material, biodegradable metal and, thin film nitinol and/or biodegradable polymer. A structural frame is formed of individual elongated pieces composed of biodegradable metal. These pieces are joined together by connector pieces composed of superelastic material. At least a portion of the structural frame has deposited thereon the thin film nitinol and/or biodegradable polymer. The structural frame of the device is collapsible for insertion in a delivery tube and, recoverable for deployment and placement in a vascular location of a patient body.

Abstract: The present disclosure provides methods and kits for preserving or restoring thymic functions of a subject in need thereof. The methods and kits disclosed herein include delivering an autologous thymic tissue into at least one lymph node of the subject.

Abstract: A system and method for wirelessly and passively powering and/or interrogating an implanted stent using a touch probe assembly through a near-field electrical connection not over an air interface. The stent apparatus includes at least one stent member functioning as an antenna and an electronics module coupled to the at least one stent member. Also, a wirelessly and passively powered power meter for use with implanted stents. The power meter includes an electronics module coupled to a stent member, wherein the electronics module includes a programmable oscillator structured to generate an oscillating signal that is proportional to an amount of AC power received by the implantable stent apparatus power meter through the stent member.

Abstract: It is an object of the present invention to provide methods and compositions for protection of subjects from acute kidney injury by treating the subject with compounds that modulate the cell cycle. Modulating the cell cycle can comprise inducing G0/G1 cell cycle arrest, and/or inducing cell cycle progression. As demonstrated below, even a single administration of a compound which induces G0/G1 cell cycle arrest can protect subjects from AKI, and may be used prophylactically in advance of, or as a treatment following, various treatments or conditions that are known to be injurious to the kidney, followed optionally by release of the arrest. Once AKI is established, cell cycle progression can be induced to increase replacement of lost and damaged cells.

Abstract: Methods are disclosed herein for producing a mammalian acoustic extracellular matrix (ECM) hydrogel. In further embodiments, mammalian acoustic ECM hydrogels are disclosed that are produced using the disclosed methods. Also disclosed is a mammalian acoustic ECM hydrogel, wherein the hydrogel is thermoreversible. Methods of using these acoustic ECM hydrogels are also disclosed.